Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Dada Nexus Posts Downbeat Results, Joins GDS Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Published 26/03/2024, 08:54
Updated 26/03/2024, 10:10
© Reuters.  Dada Nexus Posts Downbeat Results, Joins GDS Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining by around 70 points on Tuesday.

Shares of Dada Nexus Limited (NASDAQ: DADA) shares fell sharply in today's pre-market trading after the company reported downbeat fourth-quarter results.

The company’s board authorized share repurchase program of up to $40 million of American Depository Shares for two-year period through March 2026.

Dada Nexus shares dipped 9.1% to $2.30 in pre-market trading.

Here are some big stocks recording losses in today’s pre-market trading session.

  • GDS Holdings Limited (NASDAQ: GDS) fell 6.1% to $7.86 in pre-market trading. GDS Holdings is expected to report its fourth quarter and full year 2023 unaudited financial results today.
  • Star Bulk Carriers Corp. (NASDAQ: SBLK) shares declined 4.4% to $23.30 in pre-market trading.
  • FinVolution Group (NYSE: FINV) fell 3.9% to $4.74 in pre-market trading. FinVolution, last week, posted downbeat quarterly sales.
  • M&T Bank Corporation (NYSE: MTB) declined 3.7% to $137.00 in pre-market trading. M&T Bank is expected to report its first quarter 2024 earnings on Monday, April 15, 2024.
  • Tilray Brands, Inc. (NASDAQ: TLRY) fell 3.3% to $2.08 in pre-market trading after falling around 7% on Monday. Germany approved the legalization of cannabis for adult use.
  • MINISO Group Holding Limited (NYSE: MNSO) fell 2.6% to $20.12 in pre-market trading. MINISO Group recently reported better-than-expected second-quarter financial results.

Now Read This: Cramer Isn't 'Knocking' This Pharma Firm Anymore: 'As A Matter Of Fact, I'm Going In'

Don’t forget to check out our premarket coverage here

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.